secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0000875320-23-000015
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vertex shareholders elect all nine director nominees at 2023 annual meeting
---------------------------------------------------------------------------

- All nine director nominees elected; votes ranged from 203.8M to 223.0M in favor.
- Ernst & Young ratified as independent auditor for 2023: 226.5M for, 7.8M against.
- Advisory approval of 2022 executive compensation passed with 200.9M for (~89% of votes cast).
- Shareholders recommended annual frequency for future advisory votes (222.8M for 1 year); board adopts annual schedule.
- Non-votes on director election, compensation, and frequency proposals were 9.8M shares (broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/vrtx-20230517.htm
  HTML page:      https://secwatch.observer/filing/0000875320-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer